Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Once-Daily LY3502970 in Obesity or Overweight with Weight-Related Comorbidities
2021-002805-88Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing LY3502970 once daily with Placebo once daily (2 arms). Primary endpoint: Percent change in body weight from baseline at Week 26. Started Aug 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2021-002805-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002805-88.